Ankylosing Spondylitis News and Research

RSS
Ankylosing Spondylitis (AS) is a painful and progressive form of spinal arthritis and symptoms of inflammatory back pain often first present in people before age 35. It typically begins in the late teens and early twenties and in severe cases may result in fusing spinal vertebrae and may cause structural damage to hips and other joints. Often misdiagnosed as "just back pain" or undifferentiated arthritis, AS is a systemic inflammatory disease that, in addition to its effect on the spine, can affect internal organs, peripheral joints and vision. The Arthritis Research Campaign, estimates that on the European continent, AS prevalence ranges from 0.2 to 1 percent of the entire population. The Spondylitis Association of America estimates that between 350,000 and one million people in the U.S. suffer from Ankylosing Spondylitis.
AbbVie’s U-ACHIEVE Phase 2b/3 dose-ranging study improves outcomes in patients with ulcerative colitis

AbbVie’s U-ACHIEVE Phase 2b/3 dose-ranging study improves outcomes in patients with ulcerative colitis

Immune therapy may be potential treatment option for patients with hard-to-treat ankylosing spondylitis

Immune therapy may be potential treatment option for patients with hard-to-treat ankylosing spondylitis

Gilead Sciences presents Phase 3 results of filgotinib in biologic-experienced rheumatoid arthritis at 2018 ACR/ARHP Annual Meeting

Gilead Sciences presents Phase 3 results of filgotinib in biologic-experienced rheumatoid arthritis at 2018 ACR/ARHP Annual Meeting

MSU researchers move one step closer to solving arthritic disease in teenagers

MSU researchers move one step closer to solving arthritic disease in teenagers

Researchers discover new protein that controls level of inflammation-inducing molecule

Researchers discover new protein that controls level of inflammation-inducing molecule

Biosimilar competition may offer hope for cheaper, better psoriasis treatments in the future

Biosimilar competition may offer hope for cheaper, better psoriasis treatments in the future

Combination of NSAIDs and TNF inhibitors linked to reduced radiographic progression in AS patients

Combination of NSAIDs and TNF inhibitors linked to reduced radiographic progression in AS patients

Price check on drug ads: Would revealing costs help patients control spending?

Price check on drug ads: Would revealing costs help patients control spending?

New study launched to examine effects of rheumatologic agent on bone health

New study launched to examine effects of rheumatologic agent on bone health

Online consultation via mobile app reduces costs and delays for rheumatic disease patients

Online consultation via mobile app reduces costs and delays for rheumatic disease patients

New guidelines for anti-rheumatic drug management in patients having joint replacement surgery

New guidelines for anti-rheumatic drug management in patients having joint replacement surgery

Research findings provide insight into mechanisms underlying differences in efficacy of anti-TNF drugs

Research findings provide insight into mechanisms underlying differences in efficacy of anti-TNF drugs

CreakyJoints publishes new guidelines for rheumatoid arthritis patients and caregivers

CreakyJoints publishes new guidelines for rheumatoid arthritis patients and caregivers

CreakyJoints announces first patient-friendly guidelines for rheumatoid arthritis

CreakyJoints announces first patient-friendly guidelines for rheumatoid arthritis

FDA approves expanded use of systemic therapy for treating chronic moderate-to-severe pediatric psoriasis

FDA approves expanded use of systemic therapy for treating chronic moderate-to-severe pediatric psoriasis

FDA approves new biosimilar for multiple inflammatory diseases

FDA approves new biosimilar for multiple inflammatory diseases

Swimming can be effective option for treating patients with fibromyalgia pain

Swimming can be effective option for treating patients with fibromyalgia pain

Facebook advertising could be more effective way of identifying IBP patients

Facebook advertising could be more effective way of identifying IBP patients

Antibody-positive patients treated with infliximab less likely to benefit from infliximab biosimilar

Antibody-positive patients treated with infliximab less likely to benefit from infliximab biosimilar

Inflectra (infliximab-dyyb) approved for multiple indications

Inflectra (infliximab-dyyb) approved for multiple indications